IDSA News - August-September 2013  (Plain Text Version)

Return to Graphical Version

 

In this issue:
Patient Care and Science
•  IDSA Joins Forces with AASLD to Develop Hepatitis C Practice Recommendations
•  FDA Permits Marketing of First U.S. Test Labeled for Simultaneous Detection of TB Bacteria and Resistance to the Antiobiotice Rifampin
Clinical Practice Management
•  AMA Toolkit Now Available on Compliance for Revised HIPPA Rules
•  Health Care Reform Implementation Resources for Clinicians
Global ID
•  Congressional Staffers See ID Strides in Africa HIV/TB Responses
Science Speaks Blog
•  Kasisi Children’s Home: “Because of You We Can Help the Children.”
•  Short-Staffed Durban Clinic Raises Question: What is the Cost of Waiting?
•  At Urban Crossroads, Research, Care and Community Meet
•  Facing Transition to “Country Ownership,” Civil Society Representatives Highlight Populations’ Diverse Needs, Common Goals
You and Your Colleagues
•  In Memoriam: Morton N. Swartz, MD, FIDSA (1923-2013)
•  IDSA Congratulates 2013 Joint Research Award Winners
•  Check Out “My IDSA” for Latest Member News
Education and Resources
•  IDSA Offering New Maintenance of Certification Modules in HIV and HCV
Top Stories
•  IDSA/Avalere Study Demonstrates the Value of the ID Specialist
•  From the President: Year in Review
•  CDC Report Puts Spotlight on Threat of Antibiotic Resistance
•  IDSA Journal Club

 

IDSA Joins Forces with AASLD to Develop Hepatitis C Practice Recommendations

Recognizing the rapid development of hepatitis C medications coupled with increasing numbers of people being identified with hepatitis C virus (HCV) infection, IDSA in July announced a collaboration with the American Association for the Study of Liver Disease (AASLD) to develop clinical recommendations for the management of hepatitis C.

Through this collaboration, the societies will review current treatment recommendations and use evidence-based, consensus guidance to develop updated recommendations for treating and managing patients. Recommendations will be updated regularly and made available online.

Earlier this year, in a move strongly supported by IDSA and others, the Centers for Disease Control and Prevention recommended an age-based screening strategy consisting of a one-time test for HCV for those at highest risk, including everyone born between 1945 and 1965. This recommendation was endorsed by the U.S. Preventive Services Task Force in June. The broader testing recommendations likely will detect a substantial number of people who are unaware they are infected.

Currently available drugs and the next generation of direct-acting antivirals that likely will be available later this year offer the potential to treat and cure most patients with HCV infection. Therefore, up-to-date recommendations for the medical management of these patients and their treatment are critical.

Other IDSA Hepatitis C Resources:

The IDSA-AASLD collaboration is the latest effort by the Society to help ID clinicians keep pace with the rapidly changing field of hepatitis.

Earlier, IDSA launched a free, monthly webinar series, the IDSA Hepatitis C Knowledge Network, to educate members about current recommended practices to effectively identify, treat, and manage patients infected with HCV. Archived versions of the first three webinars, including a recent one by David L. Thomas, MD, FIDSA, chair of IDSA’s Hepatitis Task Force, are available online (you must be logged in to access this link). Podcasts of the webinars are also available on iTunes.

Additional clinical and educational resources on HCV are available at www.idsociety.org/Hepatitis_C, including the HCV Core Curriculum (covering from Pathogenesis to Post-SVR Management) and a Hepatitis C Management Discussion Board.